Name
Xalkori
Alternate Names
Crizotinib
Abbreviations
None
Category
Chemotherapy
Subcategory
Kinase inhibitor
NSC Number
None
Primary Site
Non Small Cell Lung Cancer (NSCLC)
Histology
Lymphoma
Remarks
July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).
January 14, 2021, the FDA approved crizotinib (Xalkori) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL
March 11, 2016 FDA approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
Crizotinib received FDA approval 8/26/11 for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test.
January 14, 2021, the FDA approved crizotinib (Xalkori) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL
March 11, 2016 FDA approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
Crizotinib received FDA approval 8/26/11 for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase-positive as detected by an FDA-approved test.
Coding
This drug should be coded